Incyte Corporation INCY reported first-quarter 2026 adjusted earnings of $1.81 per share, which beat the Zacks Consensus ...

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended March 2026, it ...

Incyte (INCY) delivered earnings and revenue surprises of +31.29% and +4.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s ...

Incyte Corp. (INCY) on Tuesday reported first-quarter earnings of $303.3 million. On a per-share basis, the Wilmington, Delaware-based company said ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Incyte today and set a price target of $110.00.

Investors in Incyte Corporation (Symbol: INCY) saw new options become available today, for the January 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Investors in Incyte Corporation (Symbol: INCY) saw new options begin trading today, for the June 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation ...

86% of patients on 400+ mg of INCA033989 had a complete or partial hematologic response. 89% of patients showed a reduction in mutCALR VAF, with 21% achieving >50% drop in just three cycles. A new ...